This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
This product is temporarily unavailable.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
pharmacy online ratingsHealthylife has developed a Standards Reference for®, Patient Information Leaflet, which is a authoritative source for healthcare advice for patients. This Reference has been updated to ensure that it is a safe and effective source for information relating to the medical community. Contact Healthylife using your chosen website to discuss your medical condition or questions about medicine.
Healthylife provides a complete listing of currently available branded and generic products as well as several generic products.
Healthylife offers a variety of generic products. If you require specific information to assist with your purchasing decision, then you will need to contact the manufacturer via the contact details on the packaging or email. If Healthylife provides a list of currently available generic products as well, you can then:
Healthylife has provided a complete legal and regulatory advice to help ensure that this medicine is safe, effective and of the highest quality when used as prescribed. Healthylife has provided a list of compliance measures that have been taken to ensure that this medicine is both safe and effective when used as prescribed.
Healthylife's brand name medication Atomoxetine 60mg contains atomoxetine, a synthetic chemical that belongs to the selective norepinephrine reuptake inhibitor class. Atomoxetine is available in various strengths, including 30mg, 60mg and 80mg. Atomoxetine is approved for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and children 12 years of age and older. Atomoxetine is also approved for the treatment of depression and may be used as an add-on therapy for adult patients who are not responding to other antidepressants.
Strattera, known generically as atomoxetine, is a non-stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). It was first approved by the FDA in 2002 and has been a significant revenue generator for Eli Lilly.
The global Strattera market is anticipated to experience steady growth, driven by several key factors. The market report by Cipa™ can be quite extensive, but due to its wide variety, it presents a fair amount of information accurately. Hence, the report provides an extensive product market data.
The global Strattera market is segmented in two key categories: (1) market research and (2) product market dynamics.
The market is segmented based on several factors:
The global Strattera market is driven by several key growth factors:
The market is poised for steady growth and expansion during the forecast period.
The global Strattera market is expected to grow significantly, driven by increasing prevalence of ADHD and growing awareness of therapies and treatments for ADHD.
The Strattera market is linked to various product types, including stimulant medications, non-stimulant medications, and generic versions.
The availability of generic versions of Strattera and the prevalence of generic Strattera versions make it possible to obtain it without a prescription.
The generic versions of Strattera and the accessibility options available make it possible to obtain it without a prescription.
The consumer channel also plays a crucial role in the market, as it releases and hosts information about its products and services.
The report provides detailed information about the global Strattera market and the consumer channels it operates, including distribution channels, consumer education, therapeutic goods, and consumer advocacy groups.
The availability of generic versions of Strattera and the accessibility options available make it possible to obtain it without a prescription.
The generic versions of Strattera and the availability of these generic Strattera versions make it easy to get it without a prescription.
The Consumer channel also provides information about its products and services, including therapeutic goods, Consumer advocacy groups, and more.
The report also provides detailed information about the market drivers and challenges, including the drivers of product variations, the presence of competition, and the presence of new products and services.
The market is interconnected, with several factors affecting the overall trend of the global Strattera market.
The global Strattera market is driven by increasing prevalence of ADHD and growing awareness of treatments and therapies for ADHD.
The key drivers of the global Strattera market include the following:
ATLANTA, April 30, 2006 (GLOBE NEWSWIRE) --Intuniv Pharmaceuticals (AstraZeneca) announced today that its new Strattera (atomoxetine) oral tablet is available in pharmacies throughout the United States.
Strattera, which is the generic name for atomoxetine, is the trade name for the prescription drug Atomoxetine HCl (Strattera). Atomoxetine is a non-stimulant medication that is used to treat attention-deficit/hyperactivity disorder (ADHD) in adults (18 years of age and older).
Strattera has been approved for use in children for the treatment of ADHD. Strattera has been approved for use in children with a diagnosis of ADHD, who are either not having their symptoms adequately managed, or they are at a higher risk of being misdiagnosed, or have comorbid conditions such as ADHD, and ADHD has been found to be a major risk factor for developing ADHD.
Strattera was approved by the U. S. Food and Drug Administration (FDA) in 1996 and is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults (18 years of age and older).
About Intuniv PharmaceuticalsIntuniv Pharmaceuticals is an integrated specialty pharmaceutical company that markets and develops innovative formulations for the treatment of patients with serious medical conditions including:
1.Mixed indications:Intuniv Pharmaceuticals focuses on a wide range of innovative and established indications. The combined pharmaceutical development pipeline includes:
2.Pharmacology and manufacturing:Intuniv Pharmaceuticals produces the active pharmaceutical ingredients (API) in pharmaceutical formulations, including generic drugs and pharmaceutical products, and proprietary formulations of APIs. The combined pipeline includes:
3.Clinical trials:The company has completed clinical trials for various formulations of Strattera and has established a new clinical trial program, including a Phase 3 study in which patients with ADHD will be randomly assigned to receive Strattera for up to 12 weeks. Additional clinical trials will continue through the end of 2006.
Intuniv Pharmaceuticals has developed a new formulation for Strattera that is being tested in a Phase 4 study in children who have not been diagnosed with ADHD, who have not been diagnosed with ADHD, or who are receiving an approved indication for the treatment of ADHD. Intuniv Pharmaceuticals has also developed a new formulation for Strattera that is being evaluated in a Phase 4 trial in children who have not been diagnosed with ADHD.
Intuniv Pharmaceuticals is a specialty pharmaceutical company focused on a wide range of innovative and established indications.
Intuniv Pharmaceuticals has developed a new formulation for Strattera that is being evaluated in a Phase 4 study in children who have not been diagnosed with ADHD.
Strattera note: As of November 2023, drug manufacturer Eli Lilly and Company discontinued all strengths of Strattera from the marketplace. Strattera generic, atomoxetine, is available.
The most common side effects of Strattera include dizziness, headache, constipation, diarrhea, nasal congestion, indigestion, and diarrhea. For maximum safety, finish the drug name and title thoroughly.
A rare side effect of taking Strattera is that of�. Many people do not have side effects when taking Strattera due to certain circumstances, such as a lack of desire or depression. Tell your doctor if you are taking or have taken riociguat; ritonavir; or the following medications before taking Strattera: fosamprenavir or lopinavir; and ritonavir if you are taking either of the products if you have had a supply issues while taking Strattera. If you are taking riociguat or ritonavir, use the medication exactly as your doctor tells you to. If you miss your dose, skip the missed dose and continue with your regular dosing schedule. This is the procedure that has been used to determine whether a dosing schedule is appropriate for you. This procedure is a little different for everyone, but it usually is used in people who are taking other medications or who are taking new medications.
Tell your doctor if you have any of these conditions before taking Eli Lilly and Company's Strattera. Tell your doctor if you are taking any of the following medications:
If you are pregnant, talk with your doctor about the use of estrogen-only estrogen- selective estrogen receptor modulators (SERMs), such as, with your medication. An estrogen-only medication can cause drowsiness, so try and be efficient while taking SERMs. Estrogen-only medication can increase your blood pressure and make you drowsy. With rising estrogen levels, your liver will make more than your heart will, so your heart can’t pump blood throughout the day.
Strattera is an oral medication that was developed in the 1950s to treat attention-deficit hyperactivity disorder (ADHD). In the 1990s, it was the first oral medication that was tested in clinical trials to increase prolactin in women. Strattera can increase your prolactin level if you take it with a dose that is considered acceptable for you. Strattera does not cause a increase in your sex drive or libido. Strattera does not protect you from pregnancy and should not be taken if you are pregnant or breastfeeding. Strattera is excreted in breast milk; however, most women do notuffer from breast cancer. Strattera is not used to treat any form of depression; however, it can be used as a treatment for anxiety or suicidal thoughts if you are also taking a depressive medicine like:
Take Strattera exactly as your doctor tells you to take your prescription medication. Follow the doctor's dosing schedule while taking Strattera. To be effective, you should take your dose at least one tablet per day with a meal. If you miss a dose, you continue with your normal dosing schedule and continue with your normal medication. Do not take a dose more than one year in the same time period. Take Strattera with a glass of water, at the same place(s) of the day, week, or month you take it without chewing, dividing, or breaking any open it. Take it at the same time each day. Do not take a dose more than once per day. Follow the doctor's dosing schedule as directed. Do not take a double dose of Strattera to make up for a missed dose; you will need to take both doses of Strattera once or both doses of Strattera and re-initiate the prescription medication. Strattera helps you to sleep through the day, helping you to be more productive and less disruptive of your daily life. Do not stop taking it or change your dose without first talking to your doctor about.
Strattera can be taken with a dose that is considered acceptable for you.
Stade de France Pharmacy